- Home
- Publications
- Publication Search
- Publication Details
Title
Gemtuzumab ozogamicin in acute myeloid leukemia
Authors
Keywords
-
Journal
LEUKEMIA
Volume 31, Issue 9, Pages 1855-1868
Publisher
Springer Nature
Online
2017-06-13
DOI
10.1038/leu.2017.187
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Impact of salvage regimens on response and overall survival in acute myeloid leukemia with induction failure
- (2017) M Wattad et al. LEUKEMIA
- The level of blast CD33 expression positively impacts the effect of gemtuzumab ozogamicin in patients with acute myeloid leukemia
- (2016) G. Olombel et al. BLOOD
- Long-term outcome of acute promyelocytic leukemia treated with all- trans -retinoic acid, arsenic trioxide, and gemtuzumab
- (2016) Yasmin Abaza et al. BLOOD
- Characterization of CD33/CD3 Tetravalent Bispecific Tandem Diabodies (TandAbs) for the Treatment of Acute Myeloid Leukemia
- (2016) U. Reusch et al. CLINICAL CANCER RESEARCH
- Liver Microvascular Injury and Thrombocytopenia of Antibody–Calicheamicin Conjugates in Cynomolgus Monkeys—Mechanism and Monitoring
- (2016) Magali Guffroy et al. CLINICAL CANCER RESEARCH
- Defining the dose of gemtuzumab ozogamicin in combination with induction chemotherapy in acute myeloid leukemia: a comparison of 3 mg/m2 with 6 mg/m2 in the NCRI AML17 Trial
- (2016) A. Burnett et al. HAEMATOLOGICA
- Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial
- (2016) Sergio Amadori et al. JOURNAL OF CLINICAL ONCOLOGY
- CD33 Expression and Its Association With Gemtuzumab Ozogamicin Response: Results From the Randomized Phase III Children’s Oncology Group Trial AAML0531
- (2016) Jessica A. Pollard et al. JOURNAL OF CLINICAL ONCOLOGY
- Expression of CD33 is a predictive factor for effect of gemtuzumab ozogamicin at different doses in adult acute myeloid leukaemia
- (2016) N Khan et al. LEUKEMIA
- Evaluation of gemtuzumab ozogamycin associated sinusoidal obstructive syndrome: Findings from an academic pharmacovigilance program review and a pharmaceutical sponsored registry
- (2016) Jametta S. Magwood-Golston et al. LEUKEMIA RESEARCH
- Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia
- (2016) Hagop M. Kantarjian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards
- (2016) Vincenzo Bronte et al. Nature Communications
- Expression and functional characterization of CD33 transcript variants in human acute myeloid leukemia
- (2016) George S. Laszlo et al. Oncotarget
- Defining the dose of gemtuzumab ozogamicin in combination with induction chemotherapy in acute myeloid leukemia: a comparison of 3 mg/m2 with 6 mg/m2 in the NCRI AML17 Trial
- (2016) A. Burnett et al. HAEMATOLOGICA
- Novel insights on the DNA interaction of calicheamicin γ1I
- (2015) Claudia Sissi et al. BIOPOLYMERS
- International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
- (2015) H. Dombret et al. BLOOD
- A randomized comparison of daunorubicin 90 mg/m 2 vs 60 mg/m 2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients
- (2015) Alan K. Burnett et al. BLOOD
- Gemtuzumab Ozogamicin Reduces Relapse Risk in FLT3/ITD Acute Myeloid Leukemia: A Report from the Children's Oncology Group
- (2015) K. Tarlock et al. CLINICAL CANCER RESEARCH
- Genetics of CD33 in Alzheimer's disease and acute myeloid leukemia
- (2015) M. Malik et al. HUMAN MOLECULAR GENETICS
- Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial
- (2015) Alan K Burnett et al. LANCET ONCOLOGY
- CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia
- (2015) S S Kenderian et al. LEUKEMIA
- Human-specific derived alleles ofCD33and other genes protect against postreproductive cognitive decline
- (2015) Flavio Schwarz et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Core-binding factor acute myeloid leukemia in first relapse: a retrospective study from the French AML Intergroup
- (2014) M.-A. Hospital et al. BLOOD
- The past and future of CD33 as therapeutic target in acute myeloid leukemia
- (2014) George S. Laszlo et al. BLOOD REVIEWS
- Gemtuzumab ozogamicin in acute myeloid leukemia revisited
- (2014) Felicitas Thol et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- CD33: increased inclusion of exon 2 implicates the Ig V-set domain in Alzheimer's disease susceptibility
- (2014) T. Raj et al. HUMAN MOLECULAR GENETICS
- Gemtuzumab Ozogamicin in Children and Adolescents With De Novo Acute Myeloid Leukemia Improves Event-Free Survival by Reducing Relapse Risk: Results From the Randomized Phase III Children's Oncology Group Trial AAML0531
- (2014) Alan S. Gamis et al. JOURNAL OF CLINICAL ONCOLOGY
- Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials
- (2014) Robert K Hills et al. LANCET ONCOLOGY
- Mcl-1 dependence predicts response to vorinostat and gemtuzumab ozogamicin in acute myeloid leukemia
- (2014) William E. Pierceall et al. LEUKEMIA RESEARCH
- Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia
- (2014) A Ehninger et al. Blood Cancer Journal
- CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330
- (2013) C. Krupka et al. BLOOD
- A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia
- (2013) S. H. Petersdorf et al. BLOOD
- SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML
- (2013) M. S. Kung Sutherland et al. BLOOD
- Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML
- (2013) G. S. Laszlo et al. BLOOD
- Gemtuzumab ozogamicin can reduce minimal residual disease in patients with childhood acute myeloid leukemia
- (2013) Carol O'Hear et al. CANCER
- Clinical Significance of CD33 Nonsynonymous Single-Nucleotide Polymorphisms in Pediatric Patients with Acute Myeloid Leukemia Treated with Gemtuzumab-Ozogamicin-Containing Chemotherapy
- (2013) L. Mortland et al. CLINICAL CANCER RESEARCH
- Antibody-based therapy of acute myeloid leukemia with gemtuzumab ozogamicin
- (2013) Roland Walter Frontiers in Bioscience-Landmark
- Efficacy and resistance of gemtuzumab ozogamicin for acute myeloid leukemia
- (2013) Akihiro Takeshita INTERNATIONAL JOURNAL OF HEMATOLOGY
- Incidence of sinusoidal obstruction syndrome following Mylotarg (gemtuzumab ozogamicin): a prospective observational study of 482 patients in routine clinical practice
- (2013) Martin S. Tallman et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Sequential Combination of Gemtuzumab Ozogamicin and Standard Chemotherapy in Older Patients With Newly Diagnosed Acute Myeloid Leukemia: Results of a Randomized Phase III Trial by the EORTC and GIMEMA Consortium (AML-17)
- (2013) Sergio Amadori et al. JOURNAL OF CLINICAL ONCOLOGY
- CD33 Alzheimer's Risk-Altering Polymorphism, CD33 Expression, and Exon 2 Splicing
- (2013) M. Malik et al. JOURNAL OF NEUROSCIENCE
- CD33 in Alzheimer's Disease
- (2013) Teng Jiang et al. MOLECULAR NEUROBIOLOGY
- CD33 Alzheimer's disease locus: altered monocyte function and amyloid biology
- (2013) Elizabeth M Bradshaw et al. NATURE NEUROSCIENCE
- Alzheimer’s Disease Risk Gene CD33 Inhibits Microglial Uptake of Amyloid Beta
- (2013) Ana Griciuc et al. NEURON
- AKT Signaling as a Novel Factor Associated with In Vitro Resistance of Human AML to Gemtuzumab Ozogamicin
- (2013) David B. Rosen et al. PLoS One
- Gemtuzumab ozogamicin as postconsolidation therapy does not prevent relapse in children with AML: results from NOPHO-AML 2004
- (2012) H. Hasle et al. BLOOD
- Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML
- (2012) J. A. Pollard et al. BLOOD
- Acute myeloid leukemia stem cells and CD33-targeted immunotherapy
- (2012) R. B. Walter et al. BLOOD
- Induction of DNA strand breaks is critical to predict the cytotoxicity of gemtuzumab ozogamicin against leukemic cells
- (2012) Takahiro Yamauchi et al. CANCER SCIENCE
- Phase 1 study of an anti-CD33 immunotoxin, humanized monoclonal antibody M195 conjugated to recombinant gelonin (HUM-195/rGEL), in patients with advanced myeloid malignancies
- (2012) G. Borthakur et al. HAEMATOLOGICA
- Randomized, phase IIb study of low-dose cytarabine and lintuzumab versus low-dose cytarabine and placebo in older adults with untreated acute myeloid leukemia
- (2012) M. A. Sekeres et al. HAEMATOLOGICA
- Differences in drug approval processes of 3 regulatory agencies: a case study of gemtuzumab ozogamicin
- (2012) Tetsuya Tanimoto et al. INVESTIGATIONAL NEW DRUGS
- Addition of Gemtuzumab Ozogamicin to Induction Chemotherapy Improves Survival in Older Patients With Acute Myeloid Leukemia
- (2012) Alan K. Burnett et al. JOURNAL OF CLINICAL ONCOLOGY
- Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study
- (2012) Sylvie Castaigne et al. LANCET
- The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison
- (2012) A K Burnett et al. LEUKEMIA
- Induction therapy of AML with ara-C plus daunorubicin versus ara-C plus gemtuzumab ozogamicin: a randomized phase II trial in elderly patients
- (2011) U. Brunnberg et al. ANNALS OF ONCOLOGY
- Autologous transplantation gives encouraging results for young adults with favorable-risk acute myeloid leukemia, but is not improved with gemtuzumab ozogamicin
- (2011) H. F. Fernandez et al. BLOOD
- SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma
- (2011) R.-O. Casasnovas et al. BLOOD
- Gemtuzumab ozogamicin in non-acute promyelocytic acute myeloid leukemia
- (2011) Marie-Luise Hütter et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Epitope mapping, expression and post-translational modifications of two isoforms of CD33 (CD33M and CD33m) on lymphoid and myeloid human cells
- (2011) A. B. Perez-Oliva et al. GLYCOBIOLOGY
- High CD33 expression levels in acute myeloid leukemia cells carrying the nucleophosmin (NPM1) mutation
- (2011) M. S. De Propris et al. HAEMATOLOGICA
- Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia
- (2011) Simona Lapusan et al. INVESTIGATIONAL NEW DRUGS
- A DNA-dependent stress response involving DNA-PK occurs in hypoxic cells and contributes to cellular adaptation to hypoxia
- (2011) F. Bouquet et al. JOURNAL OF CELL SCIENCE
- Targeted Drug Delivery by Gemtuzumab Ozogamicin: Mechanism-Based Mathematical Model for Treatment Strategy Improvement and Therapy Individualization
- (2011) Eva Jager et al. PLoS One
- Sequence of administration and methylation of SOCS3 may govern response to gemtuzumab ozogamicin in combination with conventional chemotherapy in patients with refractory or relapsed acute myelogenous leukemia (AML)
- (2010) Iris Middeldorf et al. AMERICAN JOURNAL OF HEMATOLOGY
- Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study
- (2010) B. Lowenberg et al. BLOOD
- Improved outcome of patients with low- and intermediate-risk cytogenetics acute myeloid leukemia (AML) in first relapse with gemtuzumab and cytarabine versus cytarabine
- (2010) Thomas Prebet et al. CANCER
- Circulating CD33 and its clinical value in acute leukemia
- (2010) Adam Abdool et al. EXPERIMENTAL HEMATOLOGY
- Gemtuzumab ozogamicin for the treatment of acute promyelocytic leukemia: mechanisms of action and resistance, safety and efficacy
- (2010) Massimo Breccia et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Identification of Patients With Acute Myeloblastic Leukemia Who Benefit From the Addition of Gemtuzumab Ozogamicin: Results of the MRC AML15 Trial
- (2010) Alan K. Burnett et al. JOURNAL OF CLINICAL ONCOLOGY
- Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo
- (2009) Aran F Labrijn et al. NATURE BIOTECHNOLOGY
- Anthracycline Dose Intensification in Acute Myeloid Leukemia
- (2009) Hugo F. Fernandez et al. NEW ENGLAND JOURNAL OF MEDICINE
- High-Dose Daunorubicin in Older Patients with Acute Myeloid Leukemia
- (2009) Bob Löwenberg et al. NEW ENGLAND JOURNAL OF MEDICINE
- Impaired CD163-mediated hemoglobin-scavenging and severe toxic symptoms in patients treated with gemtuzumab ozogamicin
- (2008) M. B. Maniecki et al. BLOOD
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started